Medtech firm Mainstay gathers €25m war chest to chase FDA

Medtech firm Mainstay gathers €25m war chest to chase FDA

The cash call is double the figure it had set itself earlier this year as it begins a push for US drug regulators to sign off on its back pain treatment next year

Medical device maker Mainstay has raised almost €17 million in cash from investors as it attempts to secure approval for its chronic back pain treatment.

The cash call is double the figure it had set itself earlier this year as it begins a push for US drug regulators to sign off on its treatment next year. The fundraising will also allow it to draw down a further €3 million loan.

The money is being provided by a...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post